When comparing the combination with either single agent, LXH254 or trametinib, we found significant (False Discovery Rate, FDR < 0.01) negative enrichment of cancer hallmark gene sets such as Myc targets, cell cycle (E2F targets, G2/M checkpoint), DNA repair and oxidative phosphorylation. The gene discussed is MYC; the disease is cancer.